Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.

@article{KraeberBodr1999BispecificAA,
  title={Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.},
  author={Françoise Kraeber-Bod{\'e}r{\'e} and A Faibre-Chauvet and Catherine Sa{\"i}-Maurel and Emmanuel Gautherot and Maryse Fiche and Lo{\"i}c Campion and J Le Boterff and Jacques Barbet and J. F. Chatal and Philippe Th{\'e}drez},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={1999},
  volume={40 1},
  pages={198-204}
}
UNLABELLED The purpose of this study was to compare the toxicity and efficacy of two-step radioimmunotherapy using a bispecific anticarcinoembryonic antigen (CEA)/anti-diethylenetriamine pentaacetic acid (DTPA) antibody (F6-734 bispecific monoclonal antibodies (BsMAbs) and an 131I-di-DTPA-TL bivalent hapten with F(ab')2 fragments of the same directly labeled anti-CEA 131-F6. METHODS Eight groups of nude mice subcutaneously grafted with the human TT medullary thyroid cancer cell line were… CONTINUE READING